Methods and compositions for correction of organ dysfunction

Abstract

The present invention includes compositions and methods for treating certain conditions, the composition comprising a choline compound; a cholinesterase inhibitor; and Acetyl-L-Carnitine, wherein the composition is used to treat at least one of autonomic dysfunctions or vascular diseases.

What is claimed is: 
     
         1 . A composition comprising:
 a choline compound; a cholinesterase inhibitor; and Acetyl-L-Carnitine, wherein the composition is used to treat at least one of autonomic dysfunctions or vascular diseases.   
     
     
         2 . The composition of  claim 1 , wherein the composition treats or prevents autonomic dysfunction (dysautonomia, non-familial dysautonomia, partial autoimmune autonomic neuropathy, idiopathic autonomic neuropathy, neurocardiogenic syncope). 
     
     
         3 . The composition of  claim 1 , wherein the composition treats or prevents multiple organ dysfunction (constipation, gastroparesis, idiopathic gastrointestinal dysmotility, low gastric acid production, ileocecal valve dysfunction (“ileus”), breathing difficulties, low gall bladder ejection fractions, biliary dyskinesia, acalculous gall bladder disease, Sphincter of Oddi dysfunction, low cholecystokinin (“CCK”) production, poor kidney function, non-alcoholic steatohepatitis (or “NASH”), or non-alcoholic fatty liver disease). 
     
     
         4 . The composition of  claim 1 , wherein the composition treats at least one of a genetic disorder or treats or prevents an acquired disorder of collagen (Ehlers-Danlos syndrome, Marfan's syndrome, Loeys-Dietz syndrome, Stickler syndrome, fibrillary disorders, elastin disorders, Joint Hypermobility Syndrome). 
     
     
         5 . The composition of  claim 1 , wherein the composition treats or prevents at least one of chronic infectious or fatigue syndromes (Chronic Fatigue Syndrome, Myalgic Encephalomylitis, Chronic Lyme disease, fibromyalgia or chronic pain associated with low growth hormone levels). 
     
     
         6 . The composition of  claim 1 , wherein the composition treats or prevents autoimmune disorders or multiple sclerosis. 
     
     
         7 . The composition of  claim 1 , wherein the composition treats or prevents a vascular disease and a rheumatological disease. 
     
     
         8 . The composition of  claim 1 , wherein the composition treats or prevents dry eyes, xerostomia (dry mouth), vascular disorders, poor nitric oxide production, endocrine disorders (including low growth hormone production), chronic fungal infections, or hallucinations. 
     
     
         9 . The composition of  claim 1 , wherein the composition treats or prevents dry eyes, dry mouth, or visual snow. 
     
     
         10 . The composition of  claim 1 , wherein the composition prevents or restores vascular endothelial health as determined by decreased thrombosis, vascular abnormalities, or livido reticularis. 
     
     
         11 . The composition of  claim 1 , wherein the composition comprises:
 a choline compound selected from at least one of choline at 100 mg to 1,000 mg, lecithin at 100 mg to 3 grams, or L-alpha glycerylphosphorylcholine at 30 mg to 2,400 mg;   75 mcg to 300 mcg of the cholinesterase inhibitor is huperzine A; and   50 mg to 600 mg of Acetyl-L-Carnitine.   
     
     
         12 . The composition of  claim 1 , wherein the composition further comprises at least one of Thiamin or Magnesium. 
     
     
         13 . The composition of  claim 1 , wherein the composition comprises per dose:
 a choline compound selected from at least one of choline at 100 mg to 1,000 mg, lecithin at 100 mg to 3 grams, or L-alpha glycerylphosphorylcholine at 30 mg to 2,400 mg;   75 mcg of huperzine A;   150 mg of Acetyl-L-Carnitine; and   optionally 30 mg Thiamin and 30 mg Magnesium.   
     
     
         14 . The composition of  claim 13 , wherein the range per dose is 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 250, 270, 300, 350, 400, 450, 500, 540, 600, 700, 750, 800, 900, 1,000, 1,100, 1,200, 1,300, 1,400, 1,500, 1,600, 1,700, 1,800, 1,900, 2,000, 2,100, 2,200, 2,300, 2,400, 2,500, 2,600, 2,700, 2,800, 2,900, 3,000, 30 to 2,400, 40 to 2,300, 50 to 2,000, 60 to 1,500, 70 to 1,000, 80 to 750, 90 to 2,400, 200 to 2,300, 300 to 2,200, 400 to 2,100, 500 to 2,000, 600 to 1,900, 700 to 1,800, 800 to 1,700, 900 to 1,600, 1,000 to 1,500, 1,100 to 1,400, 1,200 to 1,300, of the choline compound. 
     
     
         15 . The composition of  claim 13 , wherein the range per dose is 75, 80, 90, 100, 125, 150, 175, 200, 225, 250, 275, 300, 75 to 300, 80 to 275, 90 to 250, 100 to 225, 125 to 200, 150 to 175 mcg of huperzine A. 
     
     
         16 . The composition of  claim 1 , wherein the range per dose is 50, 75, 80, 90, 100, 125, 150, 175, 200, 225, 250, 275, 300, 325, 350, 375, 400, 425, 450, 475, 500, 525, 550, 575, 600, 50 to 600, 75 to 600, 80 to 575, 90 to 550, 100 to 525, 125 to 500, 150 to 475, 175 to 450, 200 to 425, 225 to 400, 250 to 375, 275 to 350, 300 to 325 Acetyl-L-Carnitine. 
     
     
         17 . The composition of  claim 12 , wherein the range per dose is 10, 20, 30, 40, 50, 60 mg Thiamin. 
     
     
         18 . The composition of  claim 12 , wherein the range per dose is 0.3, 0.5, 0.75, 1.0, 5, 10, 15, 20, 25, 30, 40, 50, 60, 70, 80, 90, 100 mg Magnesium. 
     
     
         19 . The composition of  claim 1 , wherein the composition is adapted to be administered prenatally, orally, intravenously, intraperitoneally, intranasally, intrapulmonary, vaginal, transdermal, rectal, subcutaneously, intracutaneously, or intramuscularly. 
     
     
         20 . The composition of  claim 1 , wherein the composition consisting essentially of:
 30 to 2,400 mg of at least one of choline, lecithin, or L-alpha glycerylphosphorylcholine;   75-300 mcg of huperzine A;   50 to 600 mg of Acetyl-L-Carnitine; and   optionally including at least one of 10-180 mg Thiamin or Magnesium.   
     
     
         21 . The composition of  claim 1 , wherein the composition consisting of:
 30 to 2,400 mg of at least one of choline, lecithin, or L-alpha glycerylphosphorylcholine;   75 mcg-300 mcg of huperzine A;   50 to 600 mg of Acetyl-L-Carnitine; and   optionally including at least one of 10-180 mg Thiamin or Magnesium.   
     
     
         22 . A method of treating a autonomic dysfunctions or vascular diseases in a subject, comprising administering to a subject in need thereof an effective amount of a composition comprising a choline compound; a cholinesterase inhibitor and Acetyl-L-Carnitine. 
     
     
         23 . The method of  claim 22 , further comprising the steps of determining if the subject has an autonomic dysfunction as is seen in a genetic or an acquired disorder of collagen (Ehlers-Danlos syndrome, Marfan's syndrome, Loeys-Dietz syndrome, Stickler syndrome, fibrillary disorders, elastin disorders, Joint Hypermobility Syndrome) and providing to the subject during pregnancy the composition. 
     
     
         24 . A method of treating a medical condition, comprising:
 identifying a subject having the disease; and   providing the patient with a medical composition that comprises:   a choline compound selected from at least one of choline at 100 mg to 1,000 mg, lecithin at 100 mg to 3 grams, or L-alpha glycerylphosphorylcholine at 30 mg to 2,400 mg;   75 mcg-300 mcg of huperzine A;   50 mg to 600 mg of Acetyl-L-Carnitine; and   10-180 mg Thiamin or Magnesium.   
     
     
         25 . A method for diagnosing post-ganglionic vagus nerve competency and effector organ function, comprising the steps of:
 identifying a patient suspected of having pre-ganglionic vagus nerve damage or symptoms thereof;   providing the patient with an effective amount of transdermal, rectal or vaginal suppository, or subcutaneous nicotine; and   determining the response of an effector organ, wherein if the effector organ functions following exposure to the nicotine, then the patient can be treated with a composition comprising a choline compound; a cholinesterase inhibitor; and Acetyl-L-Carnitine.   
     
     
         26 . The method of  claim 25 , wherein the effector organ is selected from at least one of bowel, Sphincter of Oddi, or Ileocecal valve. 
     
     
         27 . A method for treating pre-ganglionic vagus nerve damage or symptoms thereof comprising the steps of:
 identifying a patient suspected of having pre-ganglionic vagus nerve damage or symptoms thereof; and   providing the patient with an effective amount of transdermal, rectal or vaginal suppository, or subcutaneous nicotine sufficient to treat the pre-ganglionic vagus nerve damage or symptoms thereof.   
     
     
         28 . The method of  claim 27 , wherein the pre-ganglionic vagus nerve damage or symptoms thereof is determined by dysfunction of an effector organ selected from at least one of bowel, Sphincter of Oddi, or Ileocecal valve. 
     
     
         29 . The method of  claim 27 , wherein the nicotine is used so long as tolerable. 
     
     
         30 . The method of  claim 27 , wherein the nicotine treats constipation or gastroparesis.